Manufacturing autologous CAR-T products is a complicated process that can take weeks. Luckily, a lot of companies are working to shorten the manufacturing process, and thus, product turnaround or “vein-to-vein” time, in an effort to bring treatment to patients faster. In this segment from the Cell & Gene Live! Event Modernizing CAR-T Manufacturing: Is Point Of Care The Future?, panelists Jason Bock and Tal Salz discuss the biological and technological constraints around autologous CAR-T production.
Check out the full webinar available on-demand – https://www.cellandgene.com/doc/modernizing-car-t-manufacturing-is-point-of-care-the-future-0001
Source lifes cience connect YouTube